Literature DB >> 9604105

Posterior tibial tendon insufficiency. Its Diagnosis, Management, and Treatment.

R S Churchill1, J J Sferra.   

Abstract

Posterior tibial tendon dysfunction, once thought to be a rare clinical entity, has been observed to be a major cause of acquired flatfoot deformity in adults. Several risk factors have been identified, ranging from inflammatory conditions to obesity. A physical examination using a series of tests, including the single-limb rise, first-metatarsal rise sign, and the "too-many-toes" sign, used in combination with selected radiographic imaging techniques, allows classification of the severity of disease. This staging system then serves as the basis for formulating the treatment options, which include nonoperative as well as operative alternatives. Conservative treatment involves rest, anti-inflammatory medication, orthotic devices, and modifications to shoes. Operative options are numerous and include primary tendon repair, tendon transfer, osteotomies, and arthrodesis.

Entities:  

Mesh:

Year:  1998        PMID: 9604105

Source DB:  PubMed          Journal:  Am J Orthop (Belle Mead NJ)        ISSN: 1078-4519


  4 in total

1.  Choosing among 3 ankle-foot orthoses for a patient with stage II posterior tibial tendon dysfunction.

Authors:  Christopher G Neville; Jeff R Houck
Journal:  J Orthop Sports Phys Ther       Date:  2009-11       Impact factor: 4.751

2.  Effect of ankle-foot orthotic devices on foot kinematics in Stage II posterior tibial tendon dysfunction.

Authors:  Christopher Neville; Frederick R Lemley
Journal:  Foot Ankle Int       Date:  2012-05       Impact factor: 2.827

3.  Ankle and foot kinematics associated with stage II PTTD during stance.

Authors:  Jeff R Houck; Christopher G Neville; Josh Tome; Adolph S Flemister
Journal:  Foot Ankle Int       Date:  2009-06       Impact factor: 2.827

4.  Effects of obesity and foot arch height on gait mechanics: A cross-sectional study.

Authors:  Daekyoo Kim; Cara L Lewis; Simone V Gill
Journal:  PLoS One       Date:  2021-11-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.